NeuroSense Therapeutics (NASDAQ:NRSN) reported that its Phase 2b PARADIGM study of PrimeC in amyotrophic lateral sclerosis met its primary endpoint, showing a statistically significant reduction in neuron-derived TDP-43 compared with placebo at Day 180.
Replimune (NASDAQ:REPL) reported fiscal 2026 results with a net loss of $313.9 million, research and development expenses of $221.2 million, and selling, general and administrative expenses of $98.7 million.
Atlas Arteria (ASX:ALX) has lodged a sixth supplementary target’s statement with ASIC and ASX, reiterating its independent directors’ unanimous recommendation that securityholders reject IFM Global Infrastructure Fund’s off‑market cash offer for Atlas Arteria stapled securities.
Coinbase chief executive Brian Armstrong defended users' freedom to choose high-risk financial products while agreeing that trading platforms should avoid aggressively promoting betting-style products to less experienced investors.
Former company director Trent Bowden has pleaded guilty in the Perth Magistrates Court to three charges of dishonestly using his position as director of Trent Bowden Trading Pty Ltd to gain an advantage for himself, in connection with more than $1.5 million of investor funds.
US Representative William Timmons said Bitcoin (CRYPTO:BTC) and decentralised technologies could fundamentally challenge authoritarian governments during a House roundtable examining the role of digital assets in countries with restrictive financial systems.
Taiko said it has closed the attack path exploited during the June 21 bridge attack after independent security experts reviewed its security fixes.
CSL Limited (ASX:CSL) has reported that the European Medicines Agency’s CHMP has issued an opinion recommending the revocation of the EU marketing authorisation for TAVNEOS (avacopan), an in‑licensed therapy sold in EU and EEA markets by CSL Vifor affiliates.
Ripple president Monica Long will headline XRP Seoul on October 3 during Korea Blockchain Week.
Neuren Pharmaceuticals (ASX:NEU) says the European Medicines Agency’s CHMP has adopted a positive opinion, after re‑examination, recommending the European Commission grant marketing authorisation for DAYBU (trofinetide) to treat neurobehavioral symptoms of Rett syndrome in adults and children aged five and over.
GARANTA JÁ SEU GRAFA EDGE
Sign up free to unlock this feature
Vamos ativar um teste de 30 dias do Edge como presente de boas-vindas
